Lilly dustbins edivoxetine depression indication

Share this article:

Eli Lilly's Phase III test of edivoxetine for major depressive disorder is a fail. The company announced Thursday that the drug failed to surpass placebo when paired with a selective serotonin reuptake inhibitor (SSRI).

The company is dustbinning this indication, but ISI Group analyst Mark Schoenebaum wrote in his news assessment that Lilly may put the drug into the roster of possible ADHD therapies. Regardless, Schoenebaum writes Lilly's news won't upset Wall Street's opinion of the company. “Investors haven't exactly been optimistic that these Phase III trials would work, so today's news is not entirely surprising,” he writes.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters